|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
mig00005364346 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
160924s2016 nyu o 001 0 eng d |
| 005 |
20240614173250.8 |
| 020 |
|
|
|a 9781634840170
|q (electronic bk.)
|
| 020 |
|
|
|a 1634840178
|q (electronic bk.)
|
| 020 |
|
|
|z 9781634840170
|
| 020 |
|
|
|z 1634840178
|
| 035 |
|
|
|a 1WRLDSHRocn959151059
|
| 035 |
|
|
|a (OCoLC)959151059
|
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCO
|d OCLCQ
|d N$T
|d OCLCQ
|d OCLCF
|d SNK
|d DKU
|d AUW
|d IGB
|d D6H
|d VTS
|d AGLDB
|d AU@
|d OCLCO
|d G3B
|d OCLCA
|d S8J
|d S9I
|d STF
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|d OCLCQ
|
| 049 |
|
|
|a TXMM
|
| 050 |
|
4 |
|a QP572.S4
|
| 082 |
0 |
4 |
|a 612.6
|2 23
|
| 245 |
0 |
0 |
|a Anti-Müllerian hormone :
|b biology, role in ovarian function and clinical significance /
|c David B. Seifer and Reshef Tal, editors.
|
| 260 |
|
|
|a New York :
|b Nova Science Publishers, Inc.,
|c 2016.
|
| 300 |
|
|
|a 1 online resource (357 pages).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a data file
|2 rda
|
| 490 |
1 |
|
|a Obstetrics and Gynecology Advances
|
| 588 |
0 |
|
|a Print version record.
|
| 500 |
|
|
|a Includes index.
|
| 505 |
0 |
|
|a ANTI-MÜLLERIAN HORMONE BIOLOGY, ROLE IN OVARIAN FUNCTION AND CLINICAL SIGNIFICANCE; ANTI-MÜLLERIAN HORMONE BIOLOGY, ROLE IN OVARIAN FUNCTION AND CLINICAL SIGNIFICANCE; Library of Congress Cataloging-in-Publication Data; CONTENTS; FOREWORD; INTRODUCTION; REFERENCES; Chapter 1: THE RELEVANCE OF AMH TO HUMAN REPRODUCTIVE BIOLOGY AND MEDICINE; ABSTRACT; INTRODUCTION; REFERENCES; Chapter 2: BASIC BIOLOGY OF AMH: STRUCTURE, SIGNALING PATHWAYS, AND ROLE IN NORMAL FOLLICULOGENESIS; ABSTRACT; INTRODUCTION; STRUCTURE AND PROCESSING OF THE AMH PROTEIN; AMH SIGNALING PATHWAY.
|
| 505 |
8 |
|
|a EXPRESSION OF AMH AND ITS RECEPTORS IN THE OVARYROLE OF AMH IN OVARIAN PHYSIOLOGY; Inhibition of Primordial Follicle Recruitment; Inhibition of FSH Responsiveness; CONCLUSION; Questions for Further Research; REFERENCES; Chapter 3: STUDIES ON ANTI-MÜLLERIAN HORMONE PRODUCTION, ACTION, AND REGULATION IN THE PRIMATE OVARY: INSIGHT INTO HUMAN FOLLICULOGENESIS; ABSTRACT; INTRODUCTION; AMH PRODUCTION IN THE PRIMATE OVARY; AMH ACTIONS IN THE PRIMATE OVARY; AMH Actions in Preantral Follicles; AMH Actions in Antral Follicles; AMH REGULATION IN THE PRIMATE OVARY; Factors Regulating AMH.
|
| 505 |
8 |
|
|a AMH-Regulated FactorsAMH AS A MARKER FOR PRIMATE FOLLICULAR DEVELOPMENT IN VITRO; CONCLUSION; Questions for Further Research; REFERENCES; Chapter 4: OPTIONS FOR CHOOSING DIFFERENT AMH ASSAYS; ABSTRACT; INTRODUCTION; The Sources of AMH and Normal Ranges; Assay Matters; HISTORY OF AMH ASSAY DEVELOPMENT; Commercialisation of the AMH Assays; The Gen II Assay and Problems Following its Introduction; The International Standard for AMH; Assay Sensitivity and Performance; Practicalities of Batch and Automated Assays; Uses of Assays for Experimental and Routine Purposes; Timeliness and Efficiency.
|
| 505 |
8 |
|
|a Studies at the Extremes of Normal ConcentrationsNormal Ranges and Reporting; Implications for Future Applications; CONCLUSION; Questions for Further Research; REFERENCES; Chapter 5: THE VALUE OF NORMATIVE DATA ON AMH IN WOMEN; ABSTRACT; INTRODUCTION; AMH throughout Life; AMH Postnatal and During Puberty; Menstrual Cycle Variation; Circadian Rhythm in AMH; Intra-Follicular AMH Levels; AMH and Fecundability; Pregnancy; Perimenopausal Levels; Assay Issues; Areas for Further Research; REFERENCES; Chapter 6: ANTI-MÜLLERIAN HORMONE AND THE PREDICTION OF AGE AT NATURAL MENOPAUSE; ABSTRACT.
|
| 505 |
8 |
|
|a 1. INTRODUCTION2. OVERVIEW OF EXISTING EVIDENCE; 3. SUMMARY OF EXISTING EVIDENCE; CONCLUSION; Questions for Further Research; REFERENCES; Chapter 7: USING AMH FOR DETERMINING A STRATIFIED GONADOTROPIN DOSING REGIME NFOR IVF/ICSI AND OPTIMIZING OUTCOMES; ABSTRACT; 1. INTRODUCTION; 2. BIOMARKER EVALUATION FOR OPTIMIZING GONADOTROPIN DOSING; 2.1. Predictive Value of AMH -- Data from Randomized Controlled Trials; 3. CLINICAL APPLICATION OF STRATIFIED MEDICINE -- THE FE 999049 (FOLLITROPIN DELTA) CASE; 3.1. AMH Incorporated in Phase 2 Development; 3.2. Modeling and Simulation.
|
| 500 |
|
|
|a 3.2.1. Pharmacokinetic (PK) Model Step.
|
| 500 |
|
|
|a EBSCO eBook Academic Comprehensive Collection North America
|5 TMurS
|
| 650 |
|
0 |
|a Hormones, Sex.
|
| 700 |
1 |
|
|a Seifer, David B.,
|d 1955-
|1 https://id.oclc.org/worldcat/entity/E39PBJrGBjdBk6rPYkyJMfRtKd
|
| 700 |
1 |
|
|a Tal, Reshef.
|
| 730 |
0 |
|
|a WORLDSHARE SUB RECORDS
|
| 758 |
|
|
|i has work:
|a Anti-Müllerian hormone (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCGVwFMHqGmB8vxkT4hhFgC
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|t Anti-Müllerian hormone.
|d New York : Nova Science Publishers, Inc., 2016
|z 9781634840125
|
| 830 |
|
0 |
|a Obstetrics and gynecology advances.
|
| 856 |
4 |
0 |
|u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1345551&authtype=ip,sso&custid=s4672406
|z CONNECT
|3 eBooks on EBSCOhost
|t 0
|
| 907 |
|
|
|a 4636616
|b 05-27-21
|c 06-30-20
|
| 949 |
|
|
|a ho0
|
| 994 |
|
|
|a 92
|b TXM
|
| 998 |
|
|
|a wi
|d z
|
| 999 |
f |
f |
|s 11cd59e9-3756-4cde-8179-d341d99b8db4
|i c108f712-9d43-4595-a631-e996673b200d
|t 0
|
| 952 |
f |
f |
|a Middle Tennessee State University
|b Main
|c James E. Walker Library
|d Electronic Resources
|t 0
|e QP572.S4
|h Library of Congress classification
|
